Ninth listing of 2022 on Euronext Growth Milan
Laboratorio Farmaceutico Erfo SpA brings the total number of companies listed on Euronext Growth Milan to 179
Total placement volume of the offer equal to 3.45 million euros
Borsa Italiana, a subsidiary of the Euronext group, today congratulates Laboratorio Farmaceutico Erfo SpA for its listing on Euronext Growth Milano.
Laboratorio Farmaceutico Erfo SpA is an innovative SME operating in the nutraceutical sector. The company specializes in the formulation and production of food supplements which, thanks to continuous R&D carried out internally and in collaboration with the “Campus Bio-Medico” of the University of Rome and the University of Messina, are marketed based on market trends and consumer needs.
Laboratorio Farmaceutico Erfo SpA represents the ninth listing since the beginning of the year on the Borsa Italiana market dedicated to small and medium-sized enterprises, and brings to 179 the total number of companies currently listed on Euronext Growth Milan.
In the placement phase, Laboratorio Farmaceutico Erfo SpA raised €3.0 million excluding the potential exercise of an over-allotment option. If the over-allotment option is fully exercised, the total amount raised will be €3.45 million.
The free float at the time of admission was 22.22% and the market capitalization at the IPO was 13.5 million euros.
Alex Cutè, CEO and Founder of Laboratorio Farmaceutico Erfo SpA, said: “It is a source of pride and satisfaction for me to celebrate the achievement of this ambitious goal. business model, characterized by a high degree of innovation and scalability. We have a solid financial base which in 2021 has allowed us to grow at a CAGR of 26% over the period 2013-21, along with high profitability and zero debt.”
Legend: Alex Cutè, CEO and Founder, rang the bell at the market opening ceremony this morning to celebrate the company’s IPO.
About Laboratorio Farmaceutico Erfo SpA Laboratorio Farmaceutico Erfo SpA, founded in 2013, is an innovative SME operating in the nutraceutical sector. The company specializes in the formulation and production of food supplements which, thanks to continuous R&D carried out internally and in collaboration with the University of Rome “Campus Bio-Medico” and the University of Messina, are marketed following market trends and consumer needs. The company has more than 60 products in its portfolio manufactured using the latest generation industrial machinery.
The business model is developed through two strategic axes:
1. Diètnatural: business format franchise dedicated to the sale of nutraceutical products and continuous support in the nutritional journey of each customer, through versatile and high-margin commercial formulas. These products, marketed under the “DiètNatural” brand, are distributed in mono-brand proprietary centres, owned and managed by franchisees.
2. Medical division: new range of nutraceutical products launched in 2021, which are mainly distributed by pharmaceutical wholesalers to pharmacies and parapharmacies. This business unit is dedicated to specific therapeutic areas: gastroenterology and urology.